Canada Pension Plan Investment Board Buys 42,000 Shares of Harrow, Inc. (NASDAQ:HROW)

Canada Pension Plan Investment Board grew its stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 10,500.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 42,400 shares of the company's stock after purchasing an additional 42,000 shares during the period. Canada Pension Plan Investment Board owned about 0.12% of Harrow worth $1,423,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. AlphaQuest LLC lifted its stake in Harrow by 452.8% during the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock valued at $118,000 after buying an additional 2,889 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Harrow during the third quarter valued at approximately $271,000. Federated Hermes Inc. purchased a new stake in shares of Harrow in the 4th quarter valued at approximately $214,000. Maridea Wealth Management LLC acquired a new position in Harrow in the 4th quarter worth approximately $222,000. Finally, KLP Kapitalforvaltning AS purchased a new position in Harrow during the 4th quarter worth approximately $235,000. Institutional investors and hedge funds own 72.76% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. HC Wainwright restated a "buy" rating and issued a $57.00 target price on shares of Harrow in a report on Monday, March 31st. B. Riley dropped their price target on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st.

Harrow Stock Up 1.9 %

Shares of Harrow stock traded up $0.48 on Friday, hitting $25.55. 547,757 shares of the company traded hands, compared to its average volume of 503,897. Harrow, Inc. has a 12-month low of $10.04 and a 12-month high of $59.23. The company has a 50-day moving average price of $25.47 and a 200 day moving average price of $34.71. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The company has a market cap of $910.96 million, a PE ratio of -27.18 and a beta of 0.46.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.11 by $0.14. The business had revenue of $66.83 million during the quarter, compared to analysts' expectations of $66.01 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. Sell-side analysts predict that Harrow, Inc. will post -0.53 earnings per share for the current year.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.